Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036114
First received: May 7, 2002
Last updated: November 7, 2013
Last verified: April 2011

May 7, 2002
November 7, 2013
March 2000
August 2003   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00036114 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
Not Provided

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Not Provided
Interventional
Phase 3
Primary Purpose: Treatment
Alzheimer Disease
Drug: aripiprazole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
August 2003
August 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Institutionalized patients with Alzheimer's
Both
55 Years to 95 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00036114
CN138-004
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
Not Provided
Not Provided
Otsuka Pharmaceutical Development & Commercialization, Inc.
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP